about
Cellular immune selection with hepatitis C virus persistence in humansIsolation of a cellular factor that can reactivate latent HIV-1 without T cell activation.Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activationMinocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells.Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance.Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressorDisulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.A primary CD4(+) T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescenceComparison of Abbott RealTime HCV Genotype II with Versant line probe assay 2.0 for hepatitis C virus genotypingSorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibitionPeginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study.Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation.Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cellsPegylated IFN-α suppresses hepatitis C virus by promoting the DAPK-mTOR pathway.Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA.Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B.A noninvasive diagnosis of hepatic fibrosis by BioFibroScore® in chronic hepatitis C patients.Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection.Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection.Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors.Sofosbuvir-based interferon-free direct acting antiviral regimens for heart transplant recipients with chronic hepatitis C virus infection.Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 Positively Modulates Matrix Metalloproteinase-9 Production in Alveolar Macrophages upon Toll-Like Receptor 7 Signaling and Influenza Virus Infection.Viral hepatitis. HBV cure--can we pin our hopes on immunotherapy?Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.Novel pathway for induction of latent virus from resting CD4(+) T cells in the simian immunodeficiency virus/macaque model of human immunodeficiency virus type 1 latency.Serum cytokine/chemokine profiles in acute exacerbation of chronic hepatitis B: clinical and mechanistic implications.Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough.Evolution of HIV-1 in an HLA-B*57-positive patient during virologic escape.Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion.Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study.Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy.More viral mutants, less HBsAg clearance? One size may not fit all.Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy.Viral Factors Affecting the Clinical Outcomes of Chronic Hepatitis B.Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection.Vaccine-induced antigen-specific regulatory T cells attenuate the antiviral immunity against acute influenza virus infection.
P50
Q27485219-86E8ED88-59A8-4F6B-B31E-21BA8409631BQ33425135-E3336A74-8D32-478A-A63B-38E383EA2448Q33508788-BB1C3A09-763D-4AD1-9761-77A2BA38833CQ34102337-4CAE5998-2442-46A7-A07C-B81E07138582Q34289969-D505F373-6457-4D66-8C1D-7B8DAD7EDF20Q34647680-D0060B22-2525-4D2B-B93A-EA4840F65FBBQ34780395-DA309E16-BFD1-427A-9728-22C2ECC3721CQ35077057-89E1B60C-9B8E-4CC1-BE88-424D11FA098CQ35229849-62DD6310-1A3F-4629-A03B-B881D0DB091FQ35455627-5296D9AE-0A8B-420B-B0B8-F786EE780436Q35740334-BE3615E3-D165-4264-8876-33A2C141E8E8Q36330435-69CAD8CF-321C-4DC6-9A5A-41E3A921A1E6Q36845770-0BBE5898-0D8C-4C98-9523-3484E175560EQ37388295-2CA3DD43-CAB5-4DFC-B4CA-7FBF2FBD0C35Q37534152-D660D3A4-1D43-4311-B4B5-474A0947DCDAQ38649797-B76AE21C-2FE8-45EF-8B89-8E5071C3BB77Q39382273-FB9F45F7-913F-4A8B-BF96-6EAECDCABE89Q40062860-0CB1F5BD-AD8A-425A-94E6-9719F7CDE0BFQ40184140-92CE5C13-D2E7-4FC1-8BA5-9B3603E10FB1Q41412095-F0BE7ED6-7D3E-4CF9-AA4F-F71ECC091B92Q41498403-0AAA7DED-1E24-4EF2-8AA0-82F64B579CD7Q41827503-2A8FE7AD-588E-487B-AE54-6BE018B1A3BFQ41918997-6DA1DFE4-0E38-40AE-BD74-0ACB616BAAADQ41919605-FAEF0D04-0B0F-4C5E-A511-7C4E34B6B696Q42174019-F687C37B-0AAE-464B-9478-1B119B7BDF7BQ42181724-4F98F629-9169-4BF6-8777-7238A67FB5D6Q42200917-A68B5D1D-6F2E-4578-A44F-72451570D085Q42224701-05ECD966-C3CF-4930-BB89-A2F25526428AQ43226911-0F487DAC-7450-4E7A-877D-477866792052Q44082963-AC0AA306-C91E-4039-AF0B-7ADBEF90E864Q45354095-B45ABBCF-7F92-4723-8030-5BC6763FF7DEQ45387049-7C961BCF-CB47-4036-A6F2-5E2C79C83619Q46847999-2DC99B2A-5F23-41B1-811E-1E7F8300D3B8Q47262172-744D67A2-938E-408A-8AEB-A8B3AD08464CQ47558135-98D944B9-AFA6-4508-B40D-E509013D8BE4Q47575314-73D3D71F-D726-4D5F-8DFC-70D7DB9F5E6BQ52649957-BCCDD4E3-84B3-4CE9-A38B-243D2B09ECD8Q53694516-9067757A-A9B8-4EC7-A3E1-3F0814CAF026Q54269173-BA891F09-F068-4BC3-B34E-BA41666C517C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Hung-Chih Yang
@ast
Hung-Chih Yang
@en
Hung-Chih Yang
@es
Hung-Chih Yang
@nl
type
label
Hung-Chih Yang
@ast
Hung-Chih Yang
@en
Hung-Chih Yang
@es
Hung-Chih Yang
@nl
prefLabel
Hung-Chih Yang
@ast
Hung-Chih Yang
@en
Hung-Chih Yang
@es
Hung-Chih Yang
@nl
P106
P1153
8595098300
P31
P496
0000-0003-3864-9895